Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for Primary Prophylaxis of Taxotere/Cyclophosphamide-Induces Febrile Neutropenia

NCT02173262 is registered in ClinicalTrials.gov with Ottawa Hospital Research Institute as lead sponsor.

NCT NCT02173262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02173262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for Primary Prophylaxis of Taxotere/Cyclophosphamide-Induces Febrile Neutropenia
Lead sponsor
Ottawa Hospital Research Institute
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2014
Completion date
September 30, 2017
Enrollment
142 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer